Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced that members of the management team will participate in the following upcoming investor conferences:
H.C. Wainwright 23rd Annual Global Investment Conference
Monday, September 13, 2021 at 7:00 AM EDT. A webcast of the Company's presentation will be available at this link.
Cantor Global Healthcare Conference
Thursday, September 30, 2021 at 12:00 PM EDT. A webcast of the Company's presentation will be available at this link.
About Pieris Pharmaceuticals:
Pieris is a clinical-stage biotechnology company that combines leading protein engineering capabilities and deep understanding into molecular drivers of disease to develop medicines that drive local biology to produce superior clinical outcomes for patients. Our pipeline includes inhalable Anticalin proteins to treat respiratory diseases and locally-activated bispecifics for immuno-oncology. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by respiratory and immuno-oncology focused partnerships with leading pharmaceutical companies. For more information, visit www.pieris.com.
https://finance.yahoo.com/news/pieris-pharmaceuticals-participate-upcoming-investor-120000558.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.